Director Jay M. Moyes of Sintx Technologies, Inc. (NASDAQ:SINT) disclosed a purchase of 1,000 shares of the company's common stock on February 23, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at $2.91 each, bringing the total outlay for the transaction to $2,910. After the acquisition, Moyes directly holds 4,000 shares of Sintx Technologies.
At the time of the filing, Sintx's stock was trading at $2.97, a level that reflects a 45.5% decline over the past 12 months. The Form 4 filing provides a snapshot of the insider purchase but does not include commentary on motive or future plans.
Market assessments and corporate developments are converging on the company this quarter. InvestingPro's Fair Value analysis lists Sintx as appearing undervalued based on its internal assessment. However, the same InvestingPro platform includes a cautionary item among its subscriber tips, noting that Sintx is quickly burning through cash - one of 10 highlighted tips available to subscribers. The platform's juxtaposition of valuation and cash-flow concerns underscores competing data points investors may weigh.
Leadership changes are also on the near-term timeline. Sintx announced the appointment of Ryan Elmore as its new president, with the appointment taking effect March 16, 2026. Elmore joins the company with more than 15 years of experience in advanced biomaterials and medical device commercialization. His most recent role was Core Business Director at Invibio, a division of Victrex plc.
On the sell-side, Ascendiant Capital revised its valuation view, lowering its price target for Sintx from $25 to $16. Despite the reduction in target price, Ascendiant retained a Buy rating on the shares, citing valuation considerations as part of its rationale. The firm did not change its rating to a hold or sell in the published adjustment.
Taken together, the insider purchase, the incoming president, and the analyst adjustment provide a set of discrete, verifiable developments for Sintx Technologies. Each item - the Form 4 filing, the InvestingPro valuation and tip, the executive appointment, and the Ascendiant price-target change - is presented here as reported, without extrapolation beyond the sourced statements and filings.